Effect of Piperazine Oestrone Sulphate on Serum Lipids and Lipoproteins in Menopausal Women

Isaacs, A J; Havard, C. W. H.

doi:10.1530/acta.0.0850143

Cited by 6 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Robinson and Lebeau (1965) found a small but significant rise in serum triglycerides with conjugated equine oestrogens but the rise found by Notelovitz and Southwood (1974) and Bolton et af (1975) was not significant. Previous studies have indicated that oestradiol valerate had little effect on triglyceride levels (Nielsen et af, 1977;Wallentin and Larsson-Cohn, 1977) but that piperazine oestrone sulphate resulted in a significant rise in serum triglyceride concentration (Isaacs and Havard, 1977). The rise in serum triglyceride concentration with graded sequential mestranol and norethisterone has already been reported (Magnani and Moore, 1976), and Aitken et al (1971) reported a similar rise among women receiving daily mestranol.…”

Section: Discussionmentioning

confidence: 83%

The Effect of Various Regimens of Hormone Therapy on Serum Cholesterol and Triglyceride Concentrations in Postmenopausal Women

Paterson

Sturdee

Moore

et al. 1980

BJOG

View full text Add to dashboard Cite

Summary The serum cholesterol and triglyceride concentrations of 84 postmenopausal women both before and after 2, 6 and 12 months therapy with various regimens of hormone therapy were measured. There was little alteration in mean serum cholesterol concentration with cyclical oestrogens but both sequential mestranol and norethisterone and sequential oestradiol valerate and norgestrel significantly reduced the mean serum cholesterol concentration to a level similar to that found in age‐matched premenopausal women. There was a small and sometimes significant rise in serum triglyceride concentration with cyclical oestrogens. Sequential mestranol and norethisterone significantly elevated serum triglyceride levels, but sequential oestradiol valerate and norgestrel significantly depressed them. The results suggest that the progestogenic agent norgestrel has an important role to play in reducing both serum cholesterol and triglyceride levels, and that the sequential preparations, by virtue of their greater cholesterol lowering effect, should perhaps be preferred to cyclical oestrogens.

show abstract

Section: Discussionmentioning

confidence: 83%

The Effect of Various Regimens of Hormone Therapy on Serum Cholesterol and Triglyceride Concentrations in Postmenopausal Women

Paterson

Sturdee

Moore

et al. 1980

BJOG

View full text Add to dashboard Cite

show abstract

“…In a study of 19 post-HDL-cholesterol were found (25). When estrone sulphate in a dose of 1.25-2.5 mg was given to 20 postmenopausal women for 6 months a significant increase of triglycerides as well as an insignificant increase of the HDL fraction was reported (10).…”

Section: Discussionmentioning

confidence: 99%

Treatment with oral estrone sulphate in the female climacteric: I. Influence on lipids

Lagrelius

Johnson

Lunell

et al. 1981

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Twenty women in the perimenopause were studied for 12 months during which sodium-piperazine-estrone-sulphate 2.5 mg/day was given for 3 weeks out of 4 as a hormone replacement therapy. Blood samples were drawn at the start of therapy, then after 3, 6 and 12 months and analyzed for serum triglyceride, total cholesterol, cholesterol content of high density lipoprotein (HDL) fraction and the relative fatty acid composition of serum lecithin. Triglyceride levels were increased after 3 months (p less than 0.01). After that there was a gradual decline to almost pretreatment levels. Total cholesterol decreased during the latter period of treatment and became virtually normal; significantly lower levels (p less than 0.01) were found at 12 months. The HDL-cholesterol, which constitutes most of the high density lipoprotein fraction, showed a continuous increase and reached statistical significance at 12 months (p less than 0.01). This type of lipoprotein pattern is associated with a reduced risk of ischemic cardiovascular disease. After 3 and 6 months of treatment an increase in the relative content of palmitic acid in serum lecithin was seen, an increase that might indicate an altered liver lecithin synthesis, usually seen in cholestasis. However, after 12 months the palmitic acid level declined and was not significantly altered from the pretreatment value, indicating that the change was transitory.

show abstract

Cardiovascular impact of therapy and risks

Limouzin-Lamothe¹

1984

The Climacteric: An Update

View full text Add to dashboard Cite

Effect of Piperazine Oestrone Sulphate on Serum Lipids and Lipoproteins in Menopausal Women

Cited by 6 publications

References 15 publications

The Effect of Various Regimens of Hormone Therapy on Serum Cholesterol and Triglyceride Concentrations in Postmenopausal Women

The Effect of Various Regimens of Hormone Therapy on Serum Cholesterol and Triglyceride Concentrations in Postmenopausal Women

Treatment with oral estrone sulphate in the female climacteric: I. Influence on lipids

Cardiovascular impact of therapy and risks

Contact Info

Product

Resources

About